Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. 1990

G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
Department of Psychiatry, Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129.

Fluphenazine decanoate is commonly used as part of maintenance treatment of schizophrenia, but its pharmacokinetics are poorly understood. We administered a single intramuscular dose of fluphenazine decanoate to nine patients and found that plasma fluphenazine level did not decline to 50% of the peak level by day 26 in any of the patients. This means that it has a long half-life measurable in months rather than weeks.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005476 Fluphenazine A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. Flufenazin,Fluphenazine Hydrochloride,Lyogen,Prolixin,Hydrochloride, Fluphenazine
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
April 1979, British journal of clinical pharmacology,
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
May 1986, The British journal of psychiatry : the journal of mental science,
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
January 1988, Psychopharmacology,
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
October 2013, Journal of analytical toxicology,
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
March 1976, Lancet (London, England),
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
February 1976, Lancet (London, England),
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
January 1976, Lancet (London, England),
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
December 1979, Psychiatry research,
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
February 1988, Journal of clinical psychopharmacology,
G M Simpson, and K G Yadalam, and D F Levinson, and M J Stephanos, and E S Lo, and T B Cooper
July 1977, The American journal of psychiatry,
Copied contents to your clipboard!